{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:38:02Z","timestamp":1774546682868,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHS N261201300011I"],"award-info":[{"award-number":["HHS N261201300011I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008637","name":"Center for Strategic Scientific Initiatives, National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100008637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,1,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy\u2010induced peripheral neuropathy (CIPN) is a common and disabling consequence of neurotoxic therapies, yet factors that modulate the development and clinical impact of CIPN are poorly understood. This epidemiological analysis identifies risk factors for the incidence of CIPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis of Surveillance, Epidemiology, and End Results\u2013Medicare data examined predictors of incident CIPN claims among 11,149 women aged 66 years or older with American Joint Commission on Cancer (AJCC) stage II to IV breast cancer (and no secondary cancer diagnosis or preexisting neuropathy) who received chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, new CIPN claims occurred for 8.3% of patients within 1 year of starting chemotherapy. Risk emerged approximately 3 months after the start of chemotherapy and increased throughout 1 year. Paclitaxel as part of first\u2010line therapy increased CIPN risk 2.7\u2010fold in comparison with nonneurotoxic agents (15.9% vs 5.0%), with lower incidence rates for carboplatin and paclitaxel (11.9%), carboplatin and docetaxel (9.3%), carboplatin alone (7.7%), and docetaxel alone (6.6%). The CIPN incidence rate was higher for women who at the time of their breast cancer diagnosis were relatively young (within this Medicare sample), were at AJCC stage II or III, were married or had an equivalent status, and had fewer comorbidities, but it did not differ by race\/ethnicity or poverty level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These Medicare claims database findings indicate that women aged 66 years or older with breast cancer are susceptible to CIPN from taxane and\/or platinum compounds, with risk emerging approximately 3 months into treatment. Prospective studies of symptom emergence and clinical response (eg, stopping chemotherapy and adjunctive treatments) are indicated to determine how best to inform patients of this risk and to manage CIPN in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31798","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T10:41:50Z","timestamp":1541155310000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Risk of incident claims for chemotherapy\u2010induced peripheral neuropathy among women with breast cancer in a Medicare population"],"prefix":"10.1002","volume":"125","author":[{"given":"Mark K.","family":"Greenwald","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie J.","family":"Ruterbusch","sequence":"additional","affiliation":[{"name":"Department of Oncology Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Beebe\u2010Dimmer","sequence":"additional","affiliation":[{"name":"Department of Oncology Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Oncology Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrance L.","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Oncology Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Oncology Wayne State University School of Medicine Detroit Michigan"},{"name":"Karmanos Cancer Institute Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx140"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2317-x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2346"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.01.524"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-014-0459-7"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3552"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21204"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.04.012"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.15.19"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2014.10.014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.995775"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2014.12.002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00156"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00086"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos203"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00485.x"},{"key":"e_1_2_8_20_1","unstructured":"National Cancer Institute.Overview of the SEER program.https:\/\/seer.cancer.gov\/about\/overview.html. Accessed July 2017."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199308000-00006"},{"key":"e_1_2_8_22_1","unstructured":"StedmanMR Doria\u2010RoseP WarrenJL KlabundeCN MariottoA.The impact of different SEER\u2010Medicare claims\u2010based comorbidity indexes on predicting non\u2010cancer mortality for cancer patients.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity-report.html. Accessed July 2017."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0007"},{"key":"e_1_2_8_24_1","unstructured":"LoprinziCL.Prevention and treatment of chemotherapy\u2010induced peripheral neuropathy.https:\/\/www.uptodate.com\/contents\/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy. Accessed January 10 2017."},{"key":"e_1_2_8_25_1","unstructured":"GrayB.cmprsk: subdistribution analysis of competing risks. R package version 2.2\u20107.https:\/\/CRAN.R-project.org\/package=cmprsk. Published 2014. Accessed January 10 2017."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw206"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168707"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)31529-X"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181a3e50b"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6207"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27463"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.04.018"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:53:48Z","timestamp":1761868428000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,15]]}},"alternative-id":["10.1002\/cncr.31798"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31798","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"assertion":[{"value":"2018-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}